XML 17 R4.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:    
Revenues $ 29,000 $ 0
Operating expenses:    
Research and development 2,802,000 5,674,000
General and administrative 1,582,000 1,645,000
Total operating expenses 4,384,000 7,319,000
Operating loss (4,355,000) (7,319,000)
Other income:    
Foreign exchange gains (losses) 1,000 (87,000)
Interest income 2,000 116,000
Other income, net 52,000 166,000
Total other income, net 55,000 195,000
Loss before taxes (4,300,000) (7,124,000)
Income tax benefit 1,354,000 1,320,000
Net loss (2,946,000) (5,804,000)
Dividend on convertible exchangeable preferred shares 0 (50,000)
Net loss applicable to common shareholders $ (2,946,000) $ (5,854,000)
Basic and diluted earnings per common share:    
Net loss per share - diluted $ (2.27) $ (7.00)
Redeemable common shareholders    
Basic and diluted earnings per common share:    
Net loss per share - diluted 0 (7.00)
Common Stock    
Basic and diluted earnings per common share:    
Net loss per share - basic $ (2.27) $ (7.00)
Clinical trial supply    
Revenues:    
Revenues $ 29,000 $ 0